Market cap
$595m
Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.
Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.
In April 2026, we received approval in Canada of neffy 2 mg, with commercial launch by our collaboration partner, ALK, expected later in 2026. neffy has already been approved or is under regulatory review in countries representing approximately 98% of the current global epinephrine autoinjector sales market. In addition to our neffy base business, we are evaluating our intranasal epinephrine technology known as ARS-2, as a potential needle-free, on-demand rescue treatment option for acute flares in chronic spontaneous urticaria (“CSU”). …ARS Pharmaceuticals, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-13